The Impact of Type 2 Diabetes and Atorvastatin Treatment on Serum Levels of MMP-7 and MMP-8

Abstract

Aim:

Novel members of matrix metalloproteinases (MMPs), MMP-7 and MMP-8, have emerged as predictors of cardiovascular events. Our study aimed to evaluate serum MMP-7 and MMP-8 concentrations in patients with type 2 diabetes mellitus (T2DM) and the effects of atorvastatin on them.

Methods:

We enrolled 85 statin-free subjects with concomitant T2DM and hypercholesterolemia, but without overt micro-/macro-vascular complications (diabetic group – DG). 42 age- and gender-matched healthy subjects without chronic diseases or therapy served as healthy group (HG). All diabetic patients received fix dose of atorvastatin (20 mg/day). Clinical and anthropometrical parameters, lipids, fasting plasma glucose (FPG), serum MMP-7, MMP-8, their inhibitor (TIMP-1), IL-18, hsCRP and insulin resistance (HOMA-IR) were assayed at baseline in all participants and after 3 months in the DG.

Results:

At baseline, DG showed higher levels of BMI, systolic blood pressure, insulin resistance and FPG compared to HG (p<0.05). Similarly, DG appeared with elevated concentrations of MMP-7 (4.28±1.01 ng/ml vs 2.63±1.11 ng/ml, p<0.001), MMP-8 (73.07±21.96 ng/ml vs. 21.27±10.49 ng/ml, p<0.001) and inflammatory markers (WBC, hsCRP, IL-18, p<0.010). Importantly, atorvastatin treatment improved lipid profile, significantly reduced the concentrations of MMP-7, MMP-8 and inflammatory markers (p<0.01). Moreover, there was considerable suppression of both MMP-7/TIMP-1 and MMP-8/TIMP-1 ratios (p<0.01). In standard multiple regression analysis, the atorvastatin-induced reduction in MMP-7 was independently associated with LDL and IL-18 downregulation (R²=0.648, p=0.017). Similarly, IL-18 changes emerged as an independent determinant of MMP-8 alterations (R²=0.678, p=0.007).

Conclusions:

Hypercholesterolemic patients with T2DM showed elevated MMP-7 and MMP-8 serum concentrations. Atorvastatin reduced the latter concentrations and their ratio with TIMP-1. Those effects seemed mediated by the atorvastatin-induced suppression of inflammatory mediators.

ClinicalTrials.gov Identifier: NCT00636766

Key words

diabetes - MMP-7 - MMP-8 - TIMP-1 - IL-18 - statins

• References

• 1 Wielockx B, Libert C, Wilson C. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?. Cytokine Growth Factor Rev 2004; 15: 111-115
• 2 LaFramboise WA, Dhir R, Kelly LA et al. Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med 2012; 10: 157
• 3 Ban CR, Twigg SM, Franjic B et al. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res Clin Pract 2010; 87: 335-341
• 4 Gaubatz JW, Ballantyne CM, Wasserman BA et al. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol 2010; 30: 1034-1042
• 5 Herman MP, Sukhova GK, Libby P et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104: 1899-1904
• 6 Alfakry H, Sinisalo J, Paju S et al. The association of serum neutrophil markers and acute coronary syndrome. Scand J Immunol 2012; 76: 181-187
• 7 Verhoeven B, Hellings WE, Moll FL et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg 2005; 42: 1075-1081
• 8 Edkins TJ, Alhadeff JA, Kwok V et al. Development and validation of novel enzyme activity methods to assess inhibition of matrix metalloproteinases (MMPs) in human serum by antibodies against enzyme therapeutics. J Pharm Biomed Anal 2012; 70: 408-414
• 9 Kadoglou NP, Liapis CD. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin 2004; 20: 419-432
• 10 Tuomainen AM, Kormi I, Havulinna AS et al. Serum tissue-degrading proteinases and incident cardiovascular disease events. Eur J Prev Cardiol 2012; In press
• 11 Redberg RF, Benjamin EJ, Bittner V et al. American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; Preventive Cardiovascular Nurses Association . AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women’s Health Research. Circulation 2009; 120: 1296-1336
• 12 Athyros VG, Kakafika AI, Tziomalos K et al. Pleiotropic effects of statins – clinical evidence. Curr Pharm Des 2009; 15: 479-489
• 13 Ban CR, Twigg SM, Franjic B et al. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res Clin Pract 2010; 87: 335-341
• 14 Lee SH, Song KS, Sohn DH et al. Polyozellin blocks tumor necrosis factor α-induced interleukin 8 and matrix metalloproteinase 7 production in the human intestinal epithelial cell line HT-29. Arch Pharm Res 2011; 34: 91-97
• 15 Kadoglou NP, Daskalopoulou SS, Perrea D et al. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56: 173-189
• 16 Kadoglou NP, Vrabas IS, Sailer N et al. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab 2010; 36: 144-151
• 17 Vavuranakis M, Kariori MG, Kalogeras KI et al. Biomarkers as a guide of medical treatment in cardiovascular diseases. Curr Med Chem 2012; 19: 2485-2496
• 18 Jefferis BJ, Papacosta O, Owen CG et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis 2011; 217: 227-233
• 19 Winkler K, Hoffmann MM, Krane V et al. German Diabetes and Dialysis Study Investigators. Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. Eur J Clin Invest 2012; 42: 693-701
• 20 Jormsjö S, Whatling C, Walter DH et al. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001; 21: 1834-1839
• 21 Furman C, Copin C, Kandoussi M et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004; 174: 93-98
• 22 Shah VK, Shalia KK, Mashru MR et al. Role of matrix metalloproteinases in coronary artery disease. Indian Heart J 2009; 61: 44-50
• 23 Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007; 379: 48-52
• 24 Nenseter MS, Narverud I, Græsdal A et al. Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis. Cytokine 2013; 61: 194-198
• 25 Katsaros KM, Kastl SP, Zorn G et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv 2010; 3: 90-97
• 26 Alfakry H, Sinisalo J, Paju S et al. The association of serum neutrophil markers and acute coronary syndrome. Scand J Immunol 2012; 76: 181-187
• 27 Naruko T, Ueda M, Haze K et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106: 2894-2900
• 28 Djurić T, Zivković M, Stanković A et al. Plasma levels of matrix metalloproteinase-8 in patients with carotid atherosclerosis. J Clin Lab Anal 2010; 24: 246-251
• 29 Tuomainen AM, Nyyssönen K, Laukkanen JA et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007; 27: 2722-2728
• 30 Rajasekhar L, Liou LB, Chan CY et al. Matrix metalloproteinase-8 in sera and from polymorphonuclear leucocytes in rheumatoid arthritis: in vitro characterization and correlation with disease activity. Clin Exp Rheumatol 2004; 22: 597-602
• 31 Thirkettle S, Decock J, Arnold H et al. Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. J Biol Chem 2013; 288: 16282-16294
• 32 Correa FO, Gonçalves D, Figueredo CM et al. The short-term effectiveness of non-surgical treatment in reducing levels of interleukin-1beta and proteases in gingival crevicular fluid from patients with type 2 diabetes mellitus and chronic periodontitis. J Periodontol 2008; 79: 2143-2150
• 33 Hogue JC, Lamarche B, Tremblay AJ et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 380-386
• 34 Chandrasekar B, Mummidi S, Mahimainathan L et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006; 281: 15099-15109
• 35 Leu HB, Chen JW, Wu TC et al. Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Clin Cardiol 2005; 28: 423-428
• 36 Kruk M, Kalińczuk L, Pregowski J et al. Serum tissue inhibitor of metalloproteinases-1 and higher risk features of coronary plaque: a volumetric multivessel intravascular ultrasound study. Atherosclerosis 2007; 194: e57-e63
• 37 Wang W, Zhang HT, Yang XL. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling. J Cardiovasc Med (Hagerstown) 2013; 14: 265-269
• 38 Pussinen PJ, Sarna S, Puolakkainen M et al. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol 2013; 167: 362-368